Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

126.55 -0.76 (-0.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Earnings Outlook For Neurocrine Biosciences
Via Benzinga
NASDAQ:NBIX is not too expensive for the growth it is showing.
While growth is established for NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), the stock's valuation remains reasonable. 
Via Chartmill
Unveiling 13 Analyst Insights On Neurocrine Biosciences
Via Benzinga
NASDAQ:NBIX, a growth stock which is not overvalued.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
NASDAQ:NBIX, a strong growth stock, setting up for a breakout.
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Standout High-Growth Stock in a Consolidation Phase. 
Via Chartmill
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
Analyst Expectations for Neurocrine Biosciences's Future
Via Benzinga
NASDAQ:NBIX: a strong growth stock preparing for the next leg up?.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today
VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration. 
Via InvestorPlace
Amgen Stock Sees Relative Strength Rating Improve To 74
Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74. 
Via Investor's Business Daily
Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study
On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before. 
Via Investor's Business Daily
Ultragenyx Pharm Stock Hits 80-Plus Relative Strength Rating Benchmark
On Thursday, Ultragenyx Pharm stock received a positive adjustment to its Relative Strength (RS) Rating, from 77 to 81. 
Via Investor's Business Daily
Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher
On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before. 
Via Investor's Business Daily
3 Stocks at the Forefront of Medical Innovation
Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way. 
Via InvestorPlace
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
NASDAQ:NBIX—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a strong growth stock, setting up for a breakout. 
Via Chartmill
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation.
While growth is established for NASDAQ:NBIX, the stock's valuation remains reasonable. 
Via Chartmill
Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84. 
Via Investor's Business Daily
The 3 Most Undervalued Biotech Stocks to Buy in December
Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks. 
Via InvestorPlace
Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days
Cassava Sciences sees its Relative Strength Rating reach the 80-plus level. 
Via Investor's Business Daily
Are These Biotechs Ready To Launch?
Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and... 
Via Talk Markets
TG Therapeutics Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93. 
Via Investor's Business Daily
Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise
Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
Investors seeking growth at a reasonable cost should explore NASDAQ:NBIX.
Investors seeking growth at a reasonable cost should explore NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News
CRISPR Therapeutics sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating
Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86. 
Via Investor's Business Daily
Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade
Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before. 
Via Investor's Business Daily
Why Is Neurocrine Biosciences Stock Trading Lower Today?
Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX)  
Via Benzinga
3 Biotech Moonshots to Bet on the Future of Health
Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Rocket Pharmaceuticals Stock Sees Improved Price Strength
On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78 
Via Investor's Business Daily
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.